Late arrival costs lives: 5 steps to find cancer early in Iran

Breast lumps, H. pylori, stool tests, the HPV vaccine and quitting cigarettes and opium; simple steps that save the most lives

Updated: 27 October 20263 min read12 references
Show content for:

Key points

  • Cancer found early is often curable. In Iran many patients reach a doctor late; nearly half of women with breast cancer are diagnosed at stage 3 or higher [2].
  • Stomach, breast and lung cancer cause the most cancer deaths in Iran [1]; for each there is a simple step that lowers the risk.
  • These 5 steps are cheap, have strong evidence, and most can be done at a health centre or a GP's office.
97,700
Cancer deaths in Iran in one year
GLOBOCAN 2024 estimate [1]
1
Rank of stomach cancer among cancer deaths in Iran
12,703 deaths a year [1]
45.8%
Women with breast cancer diagnosed at stage 3 or higher
Shiraz and Kermanshah study [2]

1. Have any new breast lump checked within a few weeks

At any age, even under 40, show a doctor any new lump or thickening in the breast or armpit. In an Iranian study, a third of patients had delayed more than 3 months, and delay was linked to more advanced stage [2]. In studies worldwide, a delay of 3 months or more was linked to 12% lower survival [3].

Step-by-step guide: I found a lump in my breast. What should I do? · Mammography from what age? (Persian)

2. If stomach cancer runs in the family, get tested for H. pylori

The Helicobacter pylori germ is treated with a few oral medicines. In first-degree relatives of people with stomach cancer, treating this germ cut the risk of stomach cancer by more than half [4]. Also take long-lasting indigestion, weight loss, difficulty swallowing or black stools seriously.

Read more: Should I be tested for H. pylori?

3. Take the stool test, and if it is positive, have a colonoscopy

In Iran's screening programme, a faecal immunochemical test (FIT) is offered to people aged 50 to 70. In Isfahan only about 40% of people took the test, and of those with a positive result only 20% had a colonoscopy, although a quarter of these people had polyps or cancer [5]. Colonoscopy later than 10 months after a positive test was linked to more and more advanced cancer [6].

Read more: My stool test was positive. What should I do? · Colonoscopy from what age? (Persian)

4. Vaccinate girls against HPV, and women should have cervical screening

The HPV virus causes cervical cancer. HPV vaccine coverage in Iran is below 10% and there is no structured national programme [7]. In Sweden, women vaccinated before age 17 had nearly 90% less cervical cancer [8]. For women, in European trials, screening with an HPV test led to 40% fewer invasive cervical cancers than screening with a Pap smear [9].

Read more: Cervical cancer · the site's screening tool (Persian)

5. Quit cigarettes and opium, and ask about low-dose CT

Opium, whether smoked or eaten, more than doubles the risk of lung cancer and nearly triples the risk of bladder cancer [12]. For heavy smokers aged 50 to 80 (20 pack-years or more, who still smoke or quit within the last 15 years), yearly low-dose CT is recommended [11]; in the NLST trial it cut deaths from lung cancer by 20% [10].

Read more: Does opium cause cancer? · Symptoms of lung cancer (Persian)

When should I contact a doctor?

Screening is for people without symptoms. If you have symptoms, do not wait for a screening appointment; see a doctor now: a new lump anywhere on the body, unusual bleeding (from the bottom, in the urine, in sputum or between periods), unexplained weight loss, a cough or hoarseness lasting more than 3 weeks, difficulty swallowing, or a sore that does not heal.

Notes for doctors (for physicians)

Show detailsHide
For physicians

In Iran, stomach cancer is the leading cause of cancer death (12,703 deaths, 13%), followed by breast (9,400) and lung (8,355) [1]. Main gaps: a delay of more than 3 months in 34% of breast cancer patients (aOR for advanced stage 3.25) [2]; follow-up of only 20% of positive FITs in Isfahan [5]; HPV vaccine coverage below 10% [7]. Choi 2020: HR 0.45 for gastric cancer with eradication in first-degree relatives [4]. Corley 2017: OR for cancer 1.48 with colonoscopy 10 to 12 months after a positive FIT [6]. Lei 2020: IRR 0.12 with vaccination before age 17 [8]. Ronco 2014: rate ratio for invasive cancer 0.60 with HPV-based screening vs cytology [9]. USPSTF 2021: annual LDCT for ages 50 to 80 with 20 pack-years [11]. Full list of actions: 10 cheap steps that save lives.

Scientific evidence

Show detailsHide

Scientific evidence

6 items
Clinical trial · Phase 3

Family History of Gastric Cancer and Helicobacter pylori Treatment

N Engl J Med · 2020
Observational study

HPV Vaccination and the Risk of Invasive Cervical Cancer

N Engl J Med · 2020
Meta-analysis

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

The Lancet · 2014
Clinical trial

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

N Engl J Med · 2011
Clinical guideline

Screening for Lung Cancer

JAMA · 2021
Observational study

Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study

Lancet Glob Health · 2020

References

12 references
Show all references, 6 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Iran, Islamic Republic of: Globocan 2024 fact sheetInternational Agency for Research on Cancer · Global Cancer Observatory · 2024
    Source Back to text: 1 2 3 4
  2. 2
    Determinants of delay in diagnosis and end stage at presentation among breast cancer patients in Iran: a multi-center studyForoozani E, Ghiasvand R, Mohammadianpanah M, et al · Sci Rep · 2020;10:21477
    DOIPubMed Back to text: 1 2 3 4
  3. 3
    Influence of delay on survival in patients with breast cancer: a systematic reviewRichards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ · Lancet · 1999;353:1119-1126
  4. 4
    Family History of Gastric Cancer and Helicobacter pylori TreatmentChoi IJ, Kim CG, Lee JY, et al · N Engl J Med · 2020;382:427-436
    Study cardDOIPubMed Back to text: 1 2
  5. 5
    Pattern of Participation in Colorectal Cancer Screening from a Population-Based Screening Program in IranRahimi F, Fattahi N, Moghaddam SS, et al · Arch Iran Med · 2024;27:407-413
    DOIPubMed Back to text: 1 2
  6. 6
    Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at DiagnosisCorley DA, Jensen CD, Quinn VP, et al · JAMA · 2017;317:1631-1641
    DOIPubMed Back to text: 1 2
  7. 7
    Comprehensive National Strategy for HPV Prevention and Treatment in IranBabaeifard S, et al · Int J Health Policy Manag · 2025;14:9020
    DOIPubMed Back to text: 1 2
  8. 8
    HPV Vaccination and the Risk of Invasive Cervical CancerLei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al · N Engl J Med · 2020;383:1340-1348
    Study cardDOIPubMed Back to text: 1 2
  9. 9
    Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trialsRonco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al · The Lancet · 2014;383:524-532
    Study cardDOIPubMed Back to text: 1 2
  10. 10
    Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNational Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, et al · N Engl J Med · 2011;365:395-409
  11. 11
    Screening for Lung CancerUS Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, et al · JAMA · 2021;325:962
    Study cardDOIPubMed Back to text: 1 2
  12. 12
    Opium use and subsequent incidence of cancer: results from the Golestan Cohort StudySheikh M, Shakeri R, Poustchi H, et al · Lancet Glob Health · 2020;8:e649-e660

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.